The colorectal cancer study data indicate that Obatoclax mediates decreased expression of cyclin D1 via accelerating proteasome-mediated cyclin D1 degradation; the inhibition of proteasomal degradation using MG132 abrogated the ability of Obatoclax to cause decreased cyclin D1 expression. The gene discussed is CCND1; the disease is colorectal cancer.